BioBuzz: Exploring Philadelphia’s CDMOs

In the first installment of BioBuzz’s two-part CDMO series, they explored contract development and manufacturing organizations (CDMOs) that support traditional drug developers, including those focused on small and large molecules.

Philadelphia has a rich legacy in the pharmaceutical and biotech industries, particularly in the realm of contract development and manufacturing organizations (CDMOs). For decades, the city has been home to numerous CDMOs supporting both small and large-molecule drug developers. These organizations have played a vital role in the city’s growth as a life sciences hub, driving innovation and ensuring the timely production of critical therapies. In this first installment of their two-part CDMO series, they explored the essential contributions of these CDMOs to the traditional drug development process.

Abzena, a prominent CDMO and CRO specializing in bioconjugates, ADCs, and complex biologics, continues to grow its capabilities across global sites. In March 2023, the company secured $65 million in funding led by Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners. This investment supports key areas like drug discovery services, expanding cell line offerings, and enhancing fill-finish capabilities. Additionally, Abzena allocated $5 million to its Bristol, PA facility to meet the rising demand for bioconjugates and ADCs.

As part of the Bristol site’s upgrade, a new purification system will be installed to boost the efficiency of clinical manufacturing processes. This system, capable of operating at pressures up to 100 bars, will enhance pressure and flow rate capacities, ensuring Abzena can meet the complex needs of its clients.

Access the full article here